The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
William G. Herrington(Oxford Health NHS Foundation Trust), Christoph Wanner(Universitätsklinikum Würzburg), Colin Baigent(University of Oxford), Jyothis T. George(Boehringer Ingelheim (China)), David Preiss(Pontificia Universidad Católica de Chile), Maximilian von Eynatten(Nestlé (Switzerland)), Martin Landray(Gentofte Hospital), Sibylle J. Hauske(Heidelberg University), Jennifer B. Green, Richard Haynes, Natalie Staplin(University of Oxford)
Cited by 16
Related Papers
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
|New England Journal of Medicine|2016|3.6k
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19
|JAMA|2020|2.4k
Interpretation of the evidence for the efficacy and safety of statin therapy
|The Lancet|2016|1.8k